Suzhou Thery Pharmaceutical Co., Ltd.

Primary objective: This study used fenofibric acid choline sustained-release capsules developed by Suzhou Tri-Ray Pharmaceutical Co., Ltd. as the test preparation and fenofibric acid choline sustained-release capsules (trade name: Trilipix) produced by Fournier Laboratories Ireland Limited, the original manufacturer Abbvie Inc, as the reference preparation to evaluate whether the test preparation and the reference preparation are bioequivalent under fasting and postprandial administration. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

To compare the pharmacokinetic characteristics and safety of the investigational drug semaglutide injection (specification: 1.5mL:1mg) and the control drug semaglutide injection (trade name: Wegovy®, specification: 1.5mL:1mg) in healthy Chinese adult subjects after a single subcutaneous injection.

This study used BUFFERIN Combination Tab. A81 developed by Suzhou Terui Pharmaceutical Co., Ltd. as the test preparation and BUFFERIN Combination Tab. A81 developed by Lion Corporation as the reference preparation to evaluate whether the test preparation and the reference preparation are bioequivalent under fasting and postprandial administration conditions. The safety of the test preparation and the reference preparation in healthy subjects was observed.